Wireless Pulmonary Artery Pressure Monitoring Guides Management to Reduce Decompensation in Heart Failure With Preserved Ejection Fraction
Wireless Pulmonary Artery Pressure Monitoring Guides Management to Reduce Decompensation in Heart Failure With Preserved Ejection Fraction
复制标题
DOI：
10.1161/circheartfailure.113.001229
复制
发表时间：
2014-11-01
影响因子：
9.7
通讯作者：
Stevenson, Lynne Warner
中科院分区：
文献类型：
--
作者：
Adamson, Philip B.;Abraham, William T.;Stevenson, Lynne Warner
背景-没有治疗策略被证明对心力衰竭(HF)和射血分数(EF)保留的患者的人群有益。方法和结果-心脏MEMS心脏传感器允许监测压力以改善NYHA III级心力衰竭患者的预后(PONAME)试验是一项前瞻性、单盲、随机对照临床试验，测试血流动力学引导的HF治疗减少导致住院的失代偿的假设。在纳入研究的550例患者中，119例左心室射血分数=40%(平均50.6%)，430例左心室射血分数低(6个月内保留射血分数)，治疗组较对照组降低46%(发生率比0.54；95%可信区间0.38-0.70；P
Background-No treatment strategies have been demonstrated to be beneficial for the population for patients with heart failure (HF) and preserved ejection fraction (EF).Methods and Results-The CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients (CHAMPION) trial was a prospective, single-blinded, randomized controlled clinical trial testing the hypothesis that hemodynamically guided HF management decreases decompensation leading to hospitalization. Of the 550 patients enrolled in the study, 119 had left ventricular EF >= 40% (average, 50.6%), 430 patients had low left ventricular EF (6 months for preserved EF patients was 46% lower in the treatment group compared with control (incidence rate ratio, 0.54; 95% confidence interval, 0.38-0.70; P